The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Soluble IL-6 Receptor Potentiates the Antagonistic Activity of Soluble gp130 on IL-6 Responses
Abstract
Soluble receptors for several cytokines have been detected in body fluids and are believed to modulate the cytokine response by binding the ligand and thereby reducing its bioavailability. In the case of IL-6, the situation is more complex. The receptor consists of two components, including a ligand-binding α-subunit (IL-6R, gp80, or CD126), which in its soluble (s) form (sIL-6R) acts agonistically by making the ligand accessible to the second subunit, the signal transducer gp130 (CD130). Soluble forms of both receptor subunits are present in human blood. Gel filtration of iodinated IL-6 that had been incubated with human serum revealed that IL-6 is partially trapped in IL-6/sIL-6R/sgp130 ternary complexes. sgp130 from human plasma was enriched by immunoaffinity chromatography and identified as a 100-kDa protein. Functionally equivalent rsgp130 was produced in baculovirus-infected insect cells to study its antagonistic potential on four different cell types. It was found that in situations in which cells lacking membrane-bound IL-6R were stimulated with IL-6/sIL-6R complexes, sgp130 was a much more potent antagonist than it was on IL-6R-positive cells stimulated with IL-6 alone. In the latter case, the neutralizing activity of sgp130 could be markedly enhanced by addition of sIL-6R. As a consequence of these findings, sIL-6R of human plasma must be regarded as an antagonistic molecule that enhances the inhibitory activity of sgp130. Furthermore, in combination with sIL-6R, sgp130 is a promising candidate for the development of IL-6 antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768 · cited 1×
“Since IL-6 knockout mice develop normally and appear indistinguishable from wild-type mice unless they are challenged with pathogens, this cytokine seems to play a major role in host defense (6).”
BackgroundAutocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T., & Kishimoto, T. (1989) · Cell · doi:10.1016/0092-8674(89)90438-8 · Cited by 1,396
Stahl, N., Farruggella, T. J., Boulton, T. G., Zhong, Z., Darnell, J. E., & Yancopoulos, G. D. (1995) · Science · doi:10.1126/science.7871433 · Cited by 979
Lütticken, C., Wegenka, U. M., Yuan, J., Buschmann, J., Schindler, C., Ziemiecki, A., Harpur, A. G., Wilks, A. F., Yasukawa, K., Taga, T., et al. (1994) · Science · doi:10.1126/science.8272872 · Cited by 814
Self-citation
Cited by
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272
Self-citationIL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
The origins of age-related proinflammatory state
Ferrucci, L., Corsi, A., Lauretani, F., Bandinelli, S., Bartali, B., Taub, D. D., Guralnik, J. M., & Longo, D. L. (2005) · Blood · doi:10.1182/blood-2004-07-2599 · Cited by 908
Hurst, S. M., Wilkinson, T. S., McLoughlin, R. M., Jones, S., Horiuchi, S., Yamamoto, N., Rose-John, S., Fuller, G. M., Topley, N., & Jones, S. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00151-0 · Cited by 811
Soluble gp130 is the natural inhibitor of soluble interleukin‐6 receptor transsignaling responses
Jostock, T., Müllberg, J., Özbek, S., Atreya, R., Blinn, G., Voltz, N., Fischer, M., Neurath, M. F., & Rose‐John, S. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.01867.x · Cited by 641
The soluble interleukin 6 receptor: mechanisms of production and implications in disease
JONES, S. A., HORIUCHI, S., TOPLEY, N., YAMAMOTO, N., & FULLER, G. M. (2001) · The FASEB Journal · doi:10.1096/fj.99-1003rev · Cited by 623
Cytokine Balance in the Lungs of Patients with Acute Respiratory Distress Syndrome
PARK, W. Y., GOODMAN, R. B., STEINBERG, K. P., RUZINSKI, J. T., RADELLA, F., PARK, D. R., PUGIN, J., SKERRETT, S. J., HUDSON, L. D., & MARTIN, T. R. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.10.2104013 · Cited by 547
Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake
Merz, K. E., & Thurmond, D. C. (2020) · Comprehensive Physiology · doi:10.1002/cphy.c190029 · Cited by 494
Immunologic messenger molecules: Cytokines, interferons, and chemokines
Commins, S. P., Borish, L., & Steinke, J. W. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.07.008 · Cited by 479
Plasticity and cross-talk of Interleukin 6-type cytokines
Garbers, C., Hermanns, H. M., Schaper, F., Müller-Newen, G., Grötzinger, J., Rose-John, S., & Scheller, J. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.04.001 · Cited by 400
Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms
Kang, S., & Kishimoto, T. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00649-0 · Cited by 375
The IL-6/sIL-6R complex as a novel target for therapeutic approaches
Rose-John, S., Waetzig, G. H., Scheller, J., Grötzinger, J., & Seegert, D. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.5.613 · Cited by 360
Blockade of IL-6 Trans Signaling Attenuates Pulmonary Fibrosis
Le, T.-T. T., Karmouty-Quintana, H., Melicoff, E., Le, T.-T. T., Weng, T., Chen, N.-Y., Pedroza, M., Zhou, Y., Davies, J., Philip, K., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302470 · Cited by 299
The soluble Interleukin 6 receptor: Generation and role in inflammation and cancer
Chalaris, A., Garbers, C., Rabe, B., Rose-John, S., & Scheller, J. (2011) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2010.10.007 · Cited by 289
Li, G., Bauer, S., Nowak, M., Norwood, B., Tackenberg, B., Rosenow, F., Knake, S., Oertel, W. H., & Hamer, H. M. (2011) · Seizure · doi:10.1016/j.seizure.2010.12.005 · Cited by 274
Leukemia-Inhibitory Factor—Neuroimmune Modulator of Endocrine Function*
Auernhammer, C. J., & Melmed, S. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0400 · Cited by 264
Inhibition of Toll-like Receptor and Cytokine Signaling—A Unifying Theme in Ischemic Tolerance
Karikó, K., Weissman, D., & Welsh, F. A. (2004) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000145666.68576.71 · Cited by 260
Jones, S. A., & Rose-John, S. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(02)00319-1 · Cited by 255
Brenn, D., Richter, F., & Schaible, H. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22282 · Cited by 252
Interleukin 6 and liver regeneration
STREETZ, K. L., LUEDDE, T., MANNS, M. P., & TRAUTWEIN, C. (2000) · Gut · doi:10.1136/gut.47.2.309 · Cited by 238
Plasma and Cerebrospinal Fluid Interleukin-6 Concentrations in Posttraumatic Stress Disorder
Baker, D. G., Ekhator, N. N., Kasckow, J. W., Hill, K. K., Zoumakis, E., Dashevsky, B. A., Chrousos, G. P., & Geracioti Jr., T. D. (2001) · Neuroimmunomodulation · doi:10.1159/000049028 · Cited by 238
Reeh, H., Rudolph, N., Billing, U., Christen, H., Streif, S., Bullinger, E., Schliemann-Bullinger, M., Findeisen, R., Schaper, F., Huber, H. J., et al. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0356-0 · Cited by 180
“In contrast to sIL-6Rα, the soluble form of gp130 (sgp130) inhibits IL-6-induced signalling by sequestering IL-6:sIL-6Rα complexes [12, 13].”
Harbour, S. N., DiToro, D. F., Witte, S. J., Zindl, C. L., Gao, M., Schoeb, T. R., Jones, G. W., Jones, S. A., Hatton, R. D., & Weaver, C. T. (2020) · Science Immunology · doi:10.1126/sciimmunol.aaw2262 · Cited by 151
“Given that gp130 is ubiquitously expressed, the local balance between IL-6–, sIL-6R–, and sgp130 IL-6–responsive target cells thus determines the prominent mode of IL-6 signaling acting on any cell type (40).”
BackgroundIL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19
Kishimoto, T., & Kang, S. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101220-023458 · Cited by 140
Hyperstimulation With Interleukin 6 Inhibits Cell Cycle Progression After Hepatectomy in Mice
Wüstefeld, T., Rakemann, T., Kubicka, S., Manns, M. P., & Trautwein, C. (2000) · Hepatology · doi:10.1053/jhep.2000.16604 · Cited by 120
Interleukin-6 Induces Both Cell Growth and VEGF Production in Malignant Mesotheliomas
Adachi, Y., Aoki, C., Yoshio‐Hoshino, N., Takayama, K., Curiel, D. T., & Nishimoto, N. (2006) · International Journal of Cancer · doi:10.1002/ijc.22006 · Cited by 115
Abbatecola, A. M., Ferrucci, L., Grella, R., Bandinelli, S., Bonafè, M., Barbieri, M., Corsi, A. M., Lauretani, F., Franceschi, C., & Paolisso, G. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52112.x · Cited by 116
The hormetic and hermetic role of IL-6
Forcina, L., Franceschi, C., & Musarò, A. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101697 · Cited by 85
Kovacs, E. (2001) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(01)00079-8 · Cited by 33
ME3738 protects from concanavalin A‐induced liver failure via an IL‐6‐dependent mechanism
Klein, C., Wüstefeld, T., Heinrich, P. C., Streetz, K. L., Manns, M. P., & Trautwein, C. (2003) · European Journal of Immunology · doi:10.1002/eji.200323651 · Cited by 27
Self-citation
Metadata
- Authors
- Müller-Newen, G., Küster, A., Hemmann, U., Keul, R., Horsten, U., Martens, A., Graeve, L., Wijdenes, J., & Heinrich, P. C.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-12-01
- Volume
- 161
- Issue
- 11
- Pages
- 6347-6355
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2138009273
- Cited by
- 162
- References
- 5
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.